Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Dr. Wakelee on the Highlights of Adjuvant Therapy for Early Stage NSCLC
Dr West
Author
Howard (Jack) West, MD

I'm proud to say that many years ago I sent Dr. Heather Wakelee from Stanford a set of my slides on post-operative therapy for early stage NSCLC -- we' ve been friends since we were both getting started in our careers.

Flash forward several years, and now she's among the national leaders in the field of adjuvant therapy for NSCLC and leads one of the most important trials in that setting -- the ECOG 1505 trial that is testing whether there is a benefit of adding the anti-angiogenic agent avastin (bevacizumab) to standard chemo after surgery. She was kind enough to come up from the Bay Area to participate in the GRACE NSCLC Patient Education Forum back in September to provide a brief synopsis of our understanding of the current best strategies for post-operative treatment of patients with resected NSCLC. She also did a recent podcast on the overlapping subject of clinical trials in the adjuvant setting as part of an educational grant, , but this program is a more general overview.

Here is the audio and video podcast versions of her presentation, along with transcript and figures.

[powerpress]

wakelee adjuvant nsclc overview audio

wakelee-adjuvant-nsclc-overview-transcript

wakelee-adjuvant-nsclc-overview-figures

Next Previous link

Previous PostNext Post

Related Content

Online Community

A Brief Tornado.  I love the analogy Dr. Antonoff gave us to describe her presentation.  I felt it earlier too and am looking forward to going back for deeper dive.

Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".

While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".  

I hope any...

My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Recent Comments

JOIN THE CONVERSATION
My understanding of ADCs is…
By JanineT GRACE … on
Right patient, right time,…
By JanineT GRACE … on
A Brief Tornado.  I love the…
By JanineT GRACE … on
Biomarkers
By JanineT GRACE … on